DrugPatentWatch Database Preview
SELEGILINE HYDROCHLORIDE Drug Profile
» See Plans and Pricing
When do Selegiline Hydrochloride patents expire, and what generic alternatives are available?
Selegiline Hydrochloride is a drug marketed by Apotex, Lannett Co Inc, Novitium Pharma, Rising, Apotex Inc, Boscogen, Chartwell Molecules, Cosette, G And W Labs Inc, I3 Pharms, Mylan, and Somerset. and is included in fourteen NDAs.
The generic ingredient in SELEGILINE HYDROCHLORIDE is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Selegiline Hydrochloride
A generic version of SELEGILINE HYDROCHLORIDE was approved as selegiline hydrochloride by APOTEX INC on June 6th, 1997.
Summary for SELEGILINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Suppliers / Packagers: | 5 |
Bulk Api Vendors: | 53 |
Clinical Trials: | 35 |
Patent Applications: | 623 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SELEGILINE HYDROCHLORIDE at DailyMed |

Recent Clinical Trials for SELEGILINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
E-Group ICT Software Informatikai Zrt. | Phase 2 |
László Mangel | Phase 2 |
University of Oxford | N/A |
Pharmacology for SELEGILINE HYDROCHLORIDE
Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |